BRAF-mutated tumor cells are sensitive to V600E-specific inhibitors (vemurafenib and dabrafenib) [8,9,10,11], with dabrafenib currently being used in clinical trials for advanced metastatic disease in PTCs [12]. Here, BRAF is linked to metastatic neoplasm.